Literature DB >> 14733723

Immunoneutralization of procalcitonin as therapy of sepsis.

K L Becker1, E S Nylén, R H Snider, B Müller, J C White.   

Abstract

Prior studies have demonstrated that the prohormone, procalcitonin (ProCT), and its component calcitonin precursors (CTpr) are increased in the serum of septic patients, correlate with the severity of the illness, and persist for relatively long periods of time. Animal studies in septic hamsters have revealed that the administration of ProCT is toxic and that immunoneutralization with IgG that is reactive to this molecule significantly improves survival. A large animal model of a very rapidly lethal polymicrobial sepsis has been developed in the pig in order to measure continuous physiological and metabolic parameters and also to compare the effects in this animal of an immunoneutralization, which is performed late in the course of the disease, to an identical, but early, therapy. Based upon the physiological and metabolic parameters, the late therapy, which was initiated during the fourth hour at a time when pigs were nearly moribund, was found to be as beneficial as early therapy. In both late and early therapy, the only animals to survive at the predetermined time of euthanasia were those which had received immunoneutralization therapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14733723     DOI: 10.1179/096805103225003295

Source DB:  PubMed          Journal:  J Endotoxin Res        ISSN: 0968-0519


  5 in total

Review 1.  Procalcitonin in sepsis and systemic inflammation: a harmful biomarker and a therapeutic target.

Authors:  Kenneth L Becker; Richard Snider; Eric S Nylen
Journal:  Br J Pharmacol       Date:  2009-11-27       Impact factor: 8.739

2.  Alarmin HMGB1 is released in the small intestine of gnotobiotic piglets infected with enteric pathogens and its level in plasma reflects severity of sepsis.

Authors:  Alla Splichalova; Igor Splichal; Petra Chmelarova; Ilja Trebichavsky
Journal:  J Clin Immunol       Date:  2011-01-12       Impact factor: 8.317

3.  Exogenous procalcitonin evokes a pro-inflammatory cytokine response.

Authors:  Angelike P Liappis; Kevin W Gibbs; Eric S Nylen; Bona Yoon; Richard H Snider; Baochong Gao; Kenneth L Becker
Journal:  Inflamm Res       Date:  2010-10-17       Impact factor: 4.575

4.  Substantially elevated C-reactive protein (CRP), together with low levels of procalcitonin (PCT), contributes to diagnosis of fungal infection in immunocompromised patients.

Authors:  Markéta Marková; Helena Brodská; Karin Malíčková; Veronika Válková; Petr Cetkovský; Michal Kolář; Martin Haluzík
Journal:  Support Care Cancer       Date:  2013-05-28       Impact factor: 3.603

5.  Correlation of procalcitonin and C-reactive protein to inflammation, complications, and outcome during the intensive care unit course of multiple-trauma patients.

Authors:  Michael Meisner; Heide Adina; Joachim Schmidt
Journal:  Crit Care       Date:  2006-02       Impact factor: 9.097

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.